Provided by
| in € m | Q2 2026 E | Q3 2026 E | Q4 2026 E | FY 2026 E | FY 2027 E | FY 2028 E |
|---|---|---|---|---|---|---|
| Group Net sales | 1,046 | 1,048 | 1,007 | 4,113 | 4,225 | 4,333 | - Basic Chemicals, Sales | 624 | 637 | 626 | 2,504 | 2,573 | 2,661 | - Performance Chemicals, Sales | 421 | 409 | 381 | 1,586 | 1,632 | 1,677 | - Corporate, Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Group EBITDA | 183 | 192 | 187 | 780 | 826 | 864 | - Basic Chemicals, EBITDA | 128 | 140 | 145 | 551 | 579 | 606 | - Performance Chemicals, EBITDA | 85 | 76 | 67 | 299 | 312 | 333 | - Corporate, EBITDA | -26 | -26 | -28 | -71 | -60 | -46 |
| Gross DPS (€) | - | - | - | 2.43 | 2.43 | 2.43 | Capex (continuing operations) | - | - | - | -280 | -300 | -300 | Free cash flow to Solvay shareholders from continuing operations | - | - | - | 196 | 261 | 299 |
This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.